Unlocking the potential of iPSCs
Heartseed is a biotech that is pioneering a completely new treatment for heart failure, which had previously only been treated by transplantation, with an approach of practical use of iPSC-based therapy. No matter how innovative the technology is, it is meaningless if it is a “special treatment” available only to a limited number of people. What we are aiming for is a “common treatment” that anyone can easily receive at any time.
Keiichi Fukuda, our founder and CEO, began his research in the mid-1990s. In 2015, he founded Heartseed to commercialize the new therapy. As a result of bringing together a wide range of human resources and knowledge, and continuing to take on various challenges, we have overcome many challenges in the practical application of iPS cell-based medicine, and have developed original technologies for the stable manufacturing of large numbers of high-quality cardiomyocytes. We have also developed an original device to deliver the cardiomyocytes to the patient's heart.
Now, we are opening the door to a completely new treatment for heart failure that requires no special equipment, no overseas travel, and no search for donors, and even regenerative medicine as an emerging industry. We may only be at the starting line. Even so, we would like to connect the hearts of Heartseed team, partners, and patients facing treatment for heart failure, and also to connect as many lives as possible that can be saved to the future. With this belief, we will continue to move forward.
We are committed to operational excellence. From basic cell technologies to large-scale manufacturing, delivery device, fund-raising and licensing, we as a diverse team continue to innovate in medicine with a solid foundation based on co-creation and organizational growth.
We are not a company that only sells technology and know-how. Our mission is to integrate various technologies and knowledge in order to deliver the best products to patients and the medical institutions. We will create new businesses by being proactively involved in the entire process from research, development, manufacturing to distribution.
What we are aiming for is not a special treatment for only a limited number of people. It is meaningless if it does not become a common treatment that does not require any special equipment, search for donors, or overseas travel. That is why we have set ourselves the goal of industrializing regenerative medicine.